跳至主要内容
临床试验/NCT02544802
NCT02544802已完成1 期

Treatment of Primary Osteoarthritis of the Knee Joint With Autologous Mesenchymal Stem Cells

Steminent Biotherapeutics Inc.1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
4
试验地点
1
主要终点
Safety of intra-articular injection of autologous ADMSCs by incidence of adverse events and alterations in vital signs, blood chemistry profiles, complete blood count, urinalysis, and also the physical examination of the knees.

研究概览

简要总结

The purpose of this study is to evaluate the safety and preliminary efficacy of autologous adipose-derived mesenchymal stem cells (ADMSCs) treatment for patients with primary osteoarthritis knee. Three intra-articular injections of autologous ADMSCs will be performed to subjects at a weekly interval.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject has bilateral Kellgren and Lawrence grade II-III primary osteoarthritis as determined by X-ray.
  • Subject's pain score is 8-13 points (Lequesne's index).
  • Ages between 50-70 years.
  • Signed informed consent from the subject.
  • Female subjects should be post-menopausal women

排除标准

  • Subject infected with hepatitis B, hepatitis C, HIV, syphilis or HTLV.
  • Subject not suitable for liposuction surgery.
  • Subject with hypersensitivity/allergy to anesthetic.
  • Subject's creatinine values higher than 1.6mg/dl.
  • Subject with body mass index, BMI over
  • Subject's studied knee treated with intra-articular injection therapy within 6 months prior to screen.
  • Subject has undergone surgery on either side of knee, including fracture surgery, arthroscopic surgery, meniscus repair surgery, or cruciate ligament reconstruction surgery.
  • Subject enrolled in any other cell therapy studies within the past 30 days.
  • Subject who the investigator considers inappropriate for the clinical trial due to any other reasons than those listed above.
  • Subject has a history of gouty arthritis, septic arthritis, rheumatoid arthritis and any other autoimmune arthritis of the knee joint.
  • Subject has had major medical problems in vital organs, such as; heart, liver, kidney, or lung.

研究组 & 干预措施

ADMSCs

Experimental

Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection

干预措施: Adipose-Derived Mesenchymal Stem Cells (Drug)

结局指标

主要结局

Safety of intra-articular injection of autologous ADMSCs by incidence of adverse events and alterations in vital signs, blood chemistry profiles, complete blood count, urinalysis, and also the physical examination of the knees.

时间窗: 12 months

次要结局

  • Clinical imaging assessment of knee X-ray(12 months)
  • Clinical assessment of Short Form 36 questionnaire (SF-36)(12 months)
  • Clinical imaging assessment of MRI of the knee(12 months)
  • Clinical assessment of visual analogue scale (VAS)(12 months)
  • Clinical assessment of Hospital for Special Surgery (HSS) Knee Score(12 months)
  • Clinical assessment of Western Ontario and McMaster Universities Arthritis Index (WOMAC)(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验